GlassScriptPhysician profile
Jill Wang
NPI 1619228871
$4,180.98
in general payments reported to CMS, 2019-2025
22 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,793 · 2022: $815 · 2023: $625 · 2024: $649 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.03 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $578.02 | 2021-2024 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $551.39 | 2021-2022 | |
| Abbvie INC. | $461.11 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $442.21 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $286.35 | 2021-2025 | Abilify Asimtufii, Abilify Maintena |
| Novo Nordisk INC | $243.37 | 2022-2023 | |
| Atricure, INC. | $196.92 | 2023 | |
| Axsome Therapeutics, INC. | $150.37 | 2022-2023 | Auvelity |
| Sunovion Pharmaceuticals INC. | $137.33 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $130.15 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.81 | 2021-2024 | Caplyta |
| Foundation Fusion Solutions, LLC | $115.81 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $109.12 | 2024 | Breztri |
| Indivior INC. | $104.40 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $100.00 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $88.90 | 2022 | |
| Neurocrine Biosciences, INC. | $85.98 | 2021 | |
| Medtronic, INC. | $74.28 | 2023 | Venaseal |
| Lundbeck LLC | $67.92 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $54.88 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $47.82 | 2021-2022 | |
| Noven Therapeutics, LLC | $38.84 | 2021-2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.